What Rivia does
Rivia sells an AI-powered data platform for clinical trials that unifies fragmented trial data into one foundation, uses AI agents to continuously monitor data quality and flag issues, and lets clinical teams query trial data in natural language. The company says its platform can go live in under 20 days and serves biotech and pharma customers including Storm Therapeutics, Enyo Pharma, Scancell and Alentis Therapeutics. Rivia was founded by CEO Erik Scalfaro and Tiago Kieliger and is based in Zurich.
Rivia is a research tool on Falcoscan. AI data engine that unifies and monitors clinical trial data. Falcoscan rates Rivia with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: rising. Rivia is founded in 2023, currently at Series_a stage. Pricing: Paid.